Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Betta Pharma Completes $106 Million IPO in Shenzhen

publication date: Nov 7, 2016
Betta Pharma raised $106 million via an IPO on Shenzhen's Chi-Next Exchange. Formed by returnees in 2003, Betta develops and manufactures China Class 1.1 novel drugs for cancer, diabetes, cardiovascular and cerebrovascular diseases. Icotinib (Conmana) was initially approved in China in 2011, and in 2014, it added the indication for first-line use in non-small cell lung cancer. Betta's manufacturing facilities are located in Hangzhou, and it operates an R&D lab in Beijing. In the IPO, Betta was priced at a price-earnings ratio of 23 and moved 44% higher in initial trading, where it was halted, giving Betta a market capitalization of $1.3 billion. More details....

Stock Symbol: (SHZ: 300558)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital